|
Characteristics
|
N = 53
|
|
Age (years)
|
61.1 ± 9.8a
|
|
Male, n (%)
|
27 (50.9)b
|
|
Body mass index (kg/m2) n = 52
|
24.8 ± 4.5
|
|
Abdominal girth (cm) n = 48
|
88.7 ± 9.4
|
|
Systolic blood pressure (mmHg) n = 52
|
127.9 ± 12.0
|
|
Diastolic blood pressure (mmHg) n = 52
|
73.3 ± 9.2
|
|
HbA1c (%)
|
7.1 ± 0.8
|
|
Complications
|
|
Type 2 diabetes, n (%)
|
53 (100.0)b
|
|
diabetic neuropathy, n (%)
|
10 (18.9)
|
|
diabetic nephropathy, n (%)
|
5 (9.4)
|
|
diabetic retinopathy, n (%)
|
4 (7.5)
|
|
Hypertension, n (%)
|
23 (43.4)
|
|
Coronary artery disease, n (%)
|
4 (7.5)
|
|
Cerebral artery disease, n (%)
|
1 (1.9)
|
|
Peripheral artery disease, n (%)
|
2 (3.8)
|
|
Concurrent medications
|
|
Anti-diabetic agents
| |
|
sulfonyl urea
|
28 (52.8)b
|
|
biguanide
|
25 (47.2)
|
|
α-glucosidase inhibitor
|
23 (43.4)
|
|
pioglitazone
|
10 (18.9)
|
|
Insulin
|
5 (9.4)
|
|
Anti-hypertensive agents
| |
|
angiotensin II type 1 receptor blockers (ARBs)
|
18 (34.0)b
|
|
calcium channel blockers
|
13 (24.5)
|
|
diuretics
|
7 (13.2)
|
|
angiotensin-converting enzyme inhibitors
|
5 (9.4)
|
|
Anti-lipidemic agents
| |
|
fenofibrate
|
2 (3.8)b
|
